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It has become increasing clear that alterations in cellular
metabolism have a key role in the generation and
maintenance of cancer. Some of the metabolic changes
can be attributed to the activation of oncogenes or loss of
tumor suppressors. Here, we show that the mitochondrial
sirtuin, SirT3, acts as a tumor suppressor via its ability to
suppress reactive oxygen species (ROS) and regulate
hypoxia inducible factor 1a (HIF-1a). Primary mouse
embryo ﬁbroblasts (MEFs) or tumor cell lines expressing
SirT3 short-hairpin RNA exhibit a greater potential to
proliferate, and augmented HIF-1a protein stabilization
and transcriptional activity in hypoxic conditions. SirT3
knockdown increases tumorigenesis in xenograft models,
and this is abolished by giving mice the anti-oxidant N-
acetyl cysteine. Moreover, overexpression of SirT3
inhibits stabilization of HIF-1a protein in hypoxia and
attenuates increases in HIF-1a transcriptional activity.
Critically, overexpression of SirT3 decreases tumorigen-
esis in xenografts, even when induction of the sirtuin
occurs after tumor initiation. These data suggest that
SirT3 acts to suppress the growth of tumors, at least in
part through its ability to suppress ROS and HIF-1a.
Oncogene (2011) 30, 2986–2996; doi:10.1038/onc.2011.37;
published online 28 February 2011
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Introduction
Oncogenic transformation is accompanied by a variety
of cellular changes, including changes in metabolism.
It is not known whether the alterations in metabolism
are a cause or an affect of transformation, but they can
help cancer cells to survive various stresses such as
hypoxia and glucose limitation. Some of these changes
are facilitated by the transcription factor hypoxia
inducible factor 1a (HIF-1a). HIF-1a is a heterodimer
of two basic helix-loop-helix/PAS proteins, HIF-1a and
the aryl hydrocarbon nuclear trans-locator (ARNT or
HIF-1b) (Wang et al., 1995). An alternate isoform,
HIF-2a has both overlapping and non-redundant
functions with HIF-1a (Webb et al., 2009). Both HIFa
subunits and ARNT are ubiquitously expressed,
however, the alpha subunit is labile in conditions of
normal oxygen (5–21% O2). Under hypoxic conditions
(0.5–5% O2) the HIFa subunit is stabilized, dimerizes
with ARNT, translocates to the nucleus, and subse-
quently binds to HIF response elements (HRE) within
target genes. Among HIF-1a, transcription targets are
genes involved in glucose metabolism, angiogenesis and
metastasis (Semenza, 2003), thereby tightly linking HIF-
1a-mediated transcription to tumorigenesis.
The stability of HIF-1a protein is based on the
hydroxylation of proline residues within the oxygen-
dependent degradation domain. This hydroxylation
reaction is catalyzed by a family of proline hydroxyla-
tion enzymes (Bruick and McKnight, 2001; Epstein
et al., 2001). Hydroxylated prolines serve as a binding
site for the tumor suppressor Von-Hippel Lindeu
protein (pVHL), the substrate recognition component
of the VBC-CUL-2 E3 ubiquitin ligase complex (Ivan
et al., 2001; Jaakkola et al., 2001). In hypoxic condi-
tions, HIF-1a is stabilized by inhibition of the proline
hydroxylation enzymes through reactive oxygen species
(ROS) generated from the Qo-site of complex III in the
mitochondrial electron transport chain (Bell et al.,
2007a). These ROS are necessary for hypoxic activation,
as when a mitochondrial-targeted antioxidant is added
during hypoxia HIF-1a protein is not stabilized.
Aberrant stabilization/activation of HIF-1a is asso-
ciated with different types of cancers. For example, loss
of pVHL results in normoxic stabilization of HIF-1a,
and causes renal clear cell carcinoma, phaeochromo-
cytomas, and paragangliomas (Kaelin, 2008). In addi-
tion to pVHL, loss of succinate dehydrogenase, fuma-
rate hydratase and REDD1 have been demonstrated to
stabilize and activate HIF-1a in normoxic conditions,
due to induction of ROS and mitochondrial metabolites
(Isaacs et al., 2005; Selak et al., 2005; Guzy et al., 2008;
Horak et al., 2010). Thus, tight regulation of HIF-1a
stability/activity is important to maintain cells in a
non-transformed state.
Sirtuins are NAD-dependent deactylases that share
homology to the yeast Sir2 protein. Their enzymatic
activity is regulated by the ratio of NAD to NADH;
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There are seven mammalian homologs of Sir2 with
SirT1 having the most conserved sequence to Sir2. SirT1
localizes primarily in the nucleus along with SirT6 and
SirT7. SirT2 is in the cytoplasm whereas SirT3, SirT4,
and SirT5 are localized in the mitochondria (Haigis and
Guarente, 2006). SirT1 was recently demonstrated to
negatively regulate HIF-1a activity in hypoxia by direct
deacetylation (Lim et al., 2010). This regulation is
dependent on the abundance of NAD and NADH, as
when NADH increases in hypoxia, SirT1 deacetylation
of HIF-1a is inhibited thereby allowing for sustained
activation of HIF-1a. SirT1 can also deacetylate HIF-2a
to regulate transcriptional activity (Dioum et al., 2009).
In addition, SirT6 has been shown to repress HIF-1a-
mediated transcription by binding to chromatin on
HREs and attenuating the activation of glycolytic
genes via deacetylating histones around the promoters
(Zhong et al., 2010).
Of the three mitochondrial sirtuins, SirT3 is the
most studied to date and has been linked to longevity in
humans (Bellizzi et al., 2005). Recently SirT3 was
described to act as a mitochondrial localized tumor
suppressor (Kim et al., 2010). Speciﬁcally, SirT3
deﬁciency alone is sufﬁcient for the transformation of
primary MEFs with Myc and/or RAS to from tumors in
xenograft models. These data indicate that deletion of
SirT3 replaces the need for the loss of a tumor
suppressor required for transformation of primary cells
with an oncogene. Kim and colleagues also demon-
strated that SirT3
 /  Myc/Ras MEFs exhibit increased
glycolysis, decreased oxidative phosphorylation and
increased ROS. The authors propose that loss of SirT3
promotes transformation through an increase in chro-
mosomal instability via increased production of ROS
and altered intracellular metabolism. In this study we
further investigated how SirT3 can act as a tumor
suppressor and determine whether the increased ROS
in the absence of SirT3 can effect HIF-1a activation.
We demonstrate that loss of SirT3 increases the number
of population doublings of primary MEFs and stabilizes
HIF-1a protein to activate HIF-1a target genes in
hypoxia. Moreover, we demonstrate that the absence of
SirT3 increases tumorigenesis of established cancer cells
and that this increase is dependent on ROS. Critically,
we also show that SirT3 overexpression is sufﬁcient to
impede HIF-1a stabilization in hypoxia and to inhibit
tumorigenesis, indicating a novel role of SirT3 in the
maintenance and progression of cancer.
Results
Loss of SirT3 increases ROS and allows for transforma-
tion (Kim et al., 2010). Increases in ROS are also
associated with senescence and apoptosis in primary
cells. We thus set out to determine the effect of SirT3
deletion on replicative life span of primary MEFs.
Surprisingly, we found that SirT3
 /  MEFS have
increased population doublings compared with wt
controls (Figure 1a). Another example of increased
replicative life span is found when cells are incubated in
hypoxic conditions (Parrinello et al., 2003) thereby
generating ROS, and this increase is dependent on HIF
activity (Bell et al., 2007b). Therefore, we explored
whether loss of SirT3 activates HIF. Using a synthetic
HIF-1a reporter construct (HRE-luc) that consists of
three putative HRE sites upstream of ﬁreﬂy luciferase,
we found that MEFs displayed mildly elevated HIF-1a
transcriptional activity in the absence of SirT3
(Figure 1b). Next we examined whether SirT3 has a
role in the maintenance and progression of cancer
by using established cancer cell lines. We knocked
down SirT3 in the human osteosarcoma cell line 143B
(Figure 1c) and the human colon carcinoma cell line
HCT116 with two different short-hairpin (sh)RNAs
(Figure 1d), and found that both knockdown cell lines
displayed increased proliferation (Figures 1c and d).
These data indicate that SirT3 has tumor suppressor
functions in already established cancer cell lines in
addition to its previously described role in inhibiting
transformation of primary cells (Kim et al., 2010).
Both the 143B and HCT116 SirT3 knockdown cell
lines showed a mild increase in luciferase activity when
transfected with HRE-luc (Figures 1e and f). These data
demonstrate that deleting SirT3 results in higher growth
rates in normal and established cancer cell lines, and
may increase normoxic HIF-1a activity.
We next explored whether SirT3 knockdown affected
the hypoxic activation of HIF-1a. Culturing the SirT3
knockdown cells in hypoxic conditions (1% O2) resulted
in a striking increase in the amount of HIF-1a protein
stabilized when compared with the expected increase in
the scrambled shRNA control (Figure 2a). To determine
whether there is a concomitant increase in HIF-1a
transcriptional activity we utilized the HRE-luc con-
struct. In hypoxic conditions there was a 13-fold
increase in luciferase activity in the scramble control
compared with normoxic conditions, whereas the SirT3
knockdown cells demonstrated a 70-fold increase in
luciferase activity under the same conditions
(Figure 2b). To determine the effects on endogenous
HIF-1a targets, we performed quantitative PCR on
RNA isolated from cells incubated at ambient O2 levels
or 1% O2. Levels of all putative HIF-1a targets tested,
VEGF-A, PGK-1 and PDK-1 were increased in hypoxia
in the control samples, and the loss of SirT3 further
increased these HIF-1a targets, albeit to a lesser extent
than HRE-luc (Figures 2c–e). Interestingly, there was no
increase of these targets in the SirT3 knockdown cells
cultured under normoxic conditions. This may be due to
a requirement of co-activators that are only activated in
hypoxia.
Since loss of SirT3 augments hypoxic activation
of HIF-1a, we wished to know whether SirT3 gain of
function attenuates HIF-1a in the hypoxic response.
Thus we stably expressed V5-tagged SirT3 in 143B cells
(Figure 3a), incubated cells in 1% O2 and analyzed HIF-
1a expression. The control cells had a signiﬁcant
increase of HIF-1a protein in hypoxic conditions
whereas the cells expressing SirT3 failed to stabilize
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OncogeneHIF-1a protein during hypoxia (Figure 3b). However,
both control and SirT3-expressing cells stabilized HIF-
1a protein in the presence of DMOG, a competitive
inhibitor of the proline hydroxylation enzymes. The
decrease in HIF-1a protein stability in hypoxic SirT3-
expressing cells corresponded to an attenuated tran-
scriptional response of HRE-luc (Figure 3c), as well as
the endogenous HIF-1a responsive target gene PGK1
(Figure 3d). These data demonstrate that increased
SirT3 can prevent HIF-1a stabilization in hypoxia,
reciprocal to the phenotype of SirT3 knockdown cells.
Previous work has demonstrated that addition of
exogenous ROS is sufﬁcient to stabilize and activate
HIF-1a in normoxic conditions, and ROS is necessary
for its hypoxic stabilization (Chandel et al., 2000). As
has been previously published, we observed an increase
in reactive oxygen species in SirT3
 /  primary and
immortalized MEFs (Figures 4a and b). Interestingly,
when we knocked down SirT3 in established cancer cell
lines we also observed increased ROS (Figure 4c and
Supplementary Figure S1). Further, overexpression
of SirT3 decreased basal ROS levels, as well as the
increased ROS levels mediated by antimycin A
(Figure 4d). These data suggest that the alteration of
ROS levels may be the main mechanism by which SirT3
regulates HIF-1a. To determine whether the activation
of HIF-1a in the absence of SirT3 is due to ROS, we
treated cells with antioxidants and determined the extent
of HIF-1a activation. The 143B and HCT116 cells that
have SirT3 stably knocked down were treated with
N-acetyl-cysteine (NAC), and the increase in ROS
was prevented (Supplementary Figure S1). Strikingly,
addition of NAC to primary SirT3
 /  MEFs abolished
the increase in population doublings observed in the
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Figure 1 SirT3 loss of function increases proliferation and HIF-1a activity. (a) Population doublings in primary SirT3 wild type (wt)
and SirT3
 /  (KO) MEFs cultured in normal oxygen conditions (21% O2). (b) Luciferase values from immortalized wt and KO MEFs
transfected with HRE-luciferase in normoxia. SirT3 protein levels in 143B (c) and HCT116 (d) cells stably expressing a scrambled
control shRNA (scr) or two different shRNAs that target SirT3. Both shRNA sequences increase the rate of cellular proliferation.
Relative luciferase values of 143B (e) and HCT116 (f) cells in SirT3 stable knockdown cell lines (shRNA) or a scrambled control vector
(scr) line transfected with HRE-luciferase. Error bars are s.e.m. and * indicates a P value o0.05 with two-tailed Student’s t-test.
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 /  MEFs (Figure 5a). NAC treatment
also decreased the normoxic increase of HIF-1a
transcriptional activity in 143B and HCT116 SirT3
knockdown cells (Figures 5b and c).
Hypoxia or treatment with antimycin A induces ROS
production from the Qo site of mitochondrial complex
III. The fact that SirT3 overerxpression inhibits hypoxic
activation of HIF-1a as well as antimycin A induced
ROS, thus indicates that SirT3 may be acting on
complex III. To determine if the source of the increased
ROS in the absence of SirT3 is complex III of
mitochondria, we measured HIF-1a activity in the
presence or absence of the complex III inhibitor
stigmatellin. Stigmatellin binds to the Qo site of complex
III to inhibit electron transfer and therefore the ability
of ROS to be generated from the Qo site (Breyton,
2000). Addition of stigmatellin attenuated the increase
in HRE-luciferase in the SirT3 knockdown cells
(Figures 5d and e), thereby demonstrating that the
increase in HIF-1a activity is due to ROS generated by
complex III. Knocking down SirT3 in both the 143B-
and HCT116-established cancer cell lines did not alter
protein levels of MnSOD or the cytosolic antioxidants
catalase and SOD1 (Supplementary Figure S2).
To determine whether SirT3 modulates the progres-
sion and maintenance of tumors, we preformed studies
taking advantage of the fact that HCT116 cells
are dependent on HIF for the generation of tumors in
xenograft models (Dang et al., 2006). When HCT116
cells with stable knockdown of SirT3 were injected
into the ﬂanks of Nu/Nu mice, they formed tumors with
an increased rate of growth and increased ﬁnal mass
compared with control HCT116 cells expressing a
scrambled shRNA injected in the same mouse on the
opposite ﬂank (Figures 6a–d). The tumors formed by
the injected cells maintained the SirT3 knockdown level
of expression and also had increased mRNA levels of
the pro-angiogenic HIF-1a target VEGF-A (Figure 6e),
indicating that HIF-1a activity is upregulated in these
tumors. To determine whether this difference in
tumorigenesis is due to increased ROS in the SirT3
knockdown cells, we supplied NAC to the drinking
HIF-1
-tubulin
N H N H N H N H N H N H
scr 1 2
SirT3 shRNA
scr 1 2
SirT3 shRNA
143B HCT116
N
0
10
20
30
40
50
60
70
80
90
1
4
3
B
 
R
e
l
a
t
i
v
e
 
H
R
E
 
L
u
c
i
f
e
r
a
s
e scr
shRNA1
shRNA2
* *
*
*
0
1
2
3
4
5
6
*
R
e
l
a
t
i
v
e
 
l
e
v
e
l
s
 
o
f
 
V
E
G
F
-
A
 
m
R
N
A
scr
shRNA1
shRNA2 *
0
1
2
3
4
5
6
7
*
R
e
l
a
t
i
v
e
 
l
e
v
e
l
s
 
o
f
 
P
G
K
-
1
 
m
R
N
A scr
shRNA1
shRNA2
*
N
0
1
2
3
4
5
6
7
*
R
e
l
a
t
i
v
e
 
l
e
v
e
l
s
 
o
f
 
P
D
K
-
1
 
m
R
N
A scr
shRNA1
shRNA2
*
-tubulin
HIF-1
H
NH H
NH
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Oncogenewater. In the presence of NAC, the tumors derived from
the SirT3 shRNA cells did not display an increase in the
rate of tumor growth (Figure 6c), ﬁnal mass (Figure 6d)
or VEGF-A mRNA (Figure 6e). This data implies that
SirT3 deﬁciency increases ROS to activate HIF-1a and
facilitate tumorigenesis.
The data from Figure 3 suggests that overexpression
of SirT3 might decrease the ability of cells to form
tumors. However, we were not successful in generating
HCT116 cell lines overexpressing SirT3, suggesting that
constitutive SirT3 overexpression is selected against in
this cell line. Therefore we turned to an inducible system
in order to analyze the role of SirT3 gain of function on
proliferation and tumorigenesis. We generated 143B and
HCT116 cells stably expressing doxycycline-inducible
SirT3, or GFP as a control (Figures 7a and b). When
induced by the addition of doxycycline, both the 143B
and HCT116 cells that expressed SirT3 had decreased
proliferation compared with the GFP cells and the
un-induced cells (Figures 7a and b). Next, we performed
xenograft experiments with the HCT116 GFP or SirT3
inducible cell lines. Nine days after injecting the cells the
food was switched in half the cages to food containing
doxycycline. Induction of SirT3 led to smaller tumors
compared with the induction of GFP or no induction
(Figure 7e). The rate of tumorigenesis was decreased, as
well as the ﬁnal tumor mass, with the cells that stably
induced SirT3 expression (Figures 7c and d). These data
demonstrate for the ﬁrst time that overexpression of
SirT3 indeed can inhibit the growth of established
cancer cells in xenograft models of tumorigenesis.
Discussion
Mitochondria are known to act as signaling organelles
through the generation of ROS produced by the electron
transport chain (Starkov, 2008). High levels of ROS
-
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Oncogeneresults in DNA damage as well as damage to proteins
and lipids, thereby promoting cell death, senescence or
aging (Martindale and Holbrook, 2002). At lower levels,
electron transport chain-generated ROS can promote
cell division, modulate MAP kinase signaling cascades
through regulation of phosphatases and activate tran-
scription factors (Adler et al., 1999; Havens et al., 2006).
Here we described a novel tumor suppressor function
of SirT3 due to the suppression of electron transport
chain-generated ROS. We demonstrate that as a
consequence of increased ROS in the absence of SirT3,
the pro-tumorigenic, ROS responsive transcription
factor HIF-1a is slightly activated in normoxia and
hyper-activated in hypoxia. The normoxic activation is
inhibited by the antioxidant NAC and stigmatellin, an
inhibitor of mitochondrial complex III, indicating that
ROS from complex III is involved in this activation.
Recently, two enzymes that have a role in the
detoxiﬁcation of ROS were demonstrated to be direct
targets of SirT3 (Qiu et al., 2010; Someya et al., 2010;
Tao et al., 2010). These enzymes, MnSOD and IDH2,
are localized to the matrix of the mitochondria; there-
fore they probably do not have a role in the increased
cytosolic ROS we demonstrate to activate HIF. Inter-
estingly, four of the eleven proteins that make up
complex III have been demonstrated to be acetylated
(Schwer et al., 2009). It will be interesting to determine if
acetylation of these subunits alters ROS generation from
complex III and if any of these subunits are direct
targets of SirT3.
Our data showing that SirT3 stimulates greater
HIF-1a protein stabilization in hypoxic conditions
suggests that SirT3 modulates HIF through ROS-
mediated alteration of proline hydroxylation enzyme
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Figure 6 Loss of SirT3 in established human cancer cell lines increases tumor growth and is dependent on ROS. Tumor volume
(a) and tumor mass (b) 24 days after subcutaneous injection of HCT116 scramble control and SirT3 knockdown cells in Nu/Nu mice
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proteosomal degradation of HIF-1a. Previous reports
have demonstrated that the increase in ROS in the
absence of SirT3 inhibits FOXO3a activity (Sundaresan
et al., 2009) and FOXO3a regulates expression of the
HIF-1a transcriptional inhibitor CITED2 (Bakker et al.,
2007), thus it is possible that CITED2 may have a role in
our results. However, the 143B SirT3 knockdown cells
have only slightly decreased levels of CITED2 whereas
the HCT116 knockdown cells have increased levels of
CITED2 (Supplementary Figure S3) in normoxic
conditions, indicating that affects on HIF cannot be
fully explained by this mechanism.
Using the HCT116 colon carcinoma cell line, an
established human cancer cell line, which form xeno-
grafts in a HIF-1a dependent manner, we demonstrate
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Further we demonstrate that administration of the
antioxidant NAC normalizes this increase to the level of
tumor formation of control cells. Previously it was
reported that NAC administration completely inhibits
tumor formation in xenograft models (Gao et al.,
2007). Interestingly, our NAC treated scramble shRNA
expressing cells did form tumors, which is not consistent
with the aforementioned study. This discrepancy may be
explained by the fact that in that study they pretreated
mice with NAC one week before injection whereas we
started treating with NAC on the day of injection.
Previously, SirT3 has been demonstrated to act as a
tumor suppressor by negatively regulating MnSOD/
ROS-mediated genomic instability (Kim et al., 2010).
This has major consequences for the initiation of
tumorigenesis, but is less important for the maintenance
and progression of cancers, which would be promoted
by the survival and metastasis of primary tumor cells.
Activation of HIF-1a will directly augment the tran-
scription of genes involved in angiogenesis and metas-
tasis, such as VEGF, MMP-9, lysyl oxidase and carbonic
anhydrase IX (Rankin and Giaccia, 2008). HIF-1a also
activates metabolic genes, such as PGK-1 and PFK1A,
which increase glycolysis for ATP production during
hypoxia (Semenza, 2009). In the absence of SirT3, HIF-
1a activation may thus promote the growth and spread
of tumors. The dual action of SirT3 to inhibit HIF-1a
and prevent ROS-mediated genomic instability makes
loss of SirT3 a potent oncogenic event.
If the role of SirT3 as a tumor suppressor acts
reciprocally, then activation or gain of function should
act as an inhibitor of tumorigenesis. Indeed, we
demonstrate for the ﬁrst time that overexpression of
SirT3 is able to decrease proliferation of established
cancer cell lines. Moreover, induction of SirT3 inhibits
the ability of established tumors to grow in xenograft
models. Chemical compounds that activate SirT3 may
thus be exploited to treat cancers. In addition to the
above considerations, it has been demonstrated that
hypoxic activation of HIF-1a protects tumor cells from
chemotherapeutics (Rohwer et al., 2010). Our ﬁnding
that SirT3 gain of function is sufﬁcient to suppress
the hypoxic activation of HIF-1a also indicates
that SirT3 activation may also provide therapeutic
beneﬁts by increasing the susceptibility of tumors to
chemotherapeutics.
The tumor suppressing contributions of SirT3 could
partially explain why a polymorphism in a variable
number tandem repeat regions within intron 5 of the
human SirT3 gene, which results in higher than normal
expression of SirT3, is associated with increased long-
evity in humans (Rose et al., 2003; Bellizzi et al., 2005).
A second link between SirT3 and longevity may relate
to ROS, one of the modulators of aging via damage of
DNA, proteins and lipids. Increased expression of
SirT3 could protect from aging by decreasing ROS
and increasing efﬁciency of metabolism. Numerous
reports have indicated that the HIF pathway has a role
in life span of C. elegans (Chen et al., 2009; Zhang et al.,
2009). The recent connections between SirT1, SirT6 and
HIF (Dioum et al., 2009; Lim et al., 2010; Zhong et al.,
2010) indicate that three of the seven mammalian
sirtuins regulate the HIF pathway, representing exten-
sive metabolic cross-talk between pathways that respond
to food and oxygen availability. The interactions among
these sirtuins on HIF allow for the integration of
responses to dietary (sirtuins) and hypoxic (HIF-1a)
stresses, and may lead to new approaches to age-related
diseases.
Materials and methods
Cell culture
All cells were incubated in 371C humidiﬁed incubator with 5%
CO2. HCT116 (ATCC) were cultured in McCoy’s5A (ATCC)
whereas MEFs and 143B cells were cultured in Dulbecco’s
modiﬁed Eagle medium (Sigma, St Louis, MO, USA). All the
media were supplemented with 10% fetal bovine serum
(Hyclone, South Logan, UT, USA), 100U/ml penicillin/
streptomycin (Mediatech, Manassas, VA, USA) and 20mM
HEPES (Mediatech). MEFs were isolated from E13.5 embryo
from a SirT3
þ/  x SirT3
þ/  cross. In all experiments using
NAC (Sigma), it was added the day before the experiment was
started. Except for the population doublings (5mM), NAC was
used at a concentration of 10mM. Stable cells were generated
using lentivirus or retrovirus. To monitor population dou-
blings, cells were split at approximately 70% conﬂuence,
counted, and seeded at a density of 4 10
4 cells. Population
doubling was calculated using the following formula:
PD¼log(number of cells counted/number of cells seeded)/
log2þprevious PD. Representative curves are displayed from
three independent experiments. Hypoxic conditions (1% O2)
were obtained using humidiﬁed variable aerobic workstation
InVivo2 400 (Ruskinn, Pencoed, UK).
Constructs and cloning
Full length SirT3 was cloned from mouse liver complementary
DNA as previously described (Cooper et al., 2009). To
generate a lentiviral transfer vector with V5-tagged SirT3, we
PCR ampliﬁed SirT3 and ligated it into pENTR-D-TOPO
(Invitrogen) and then recombined into pLenti4-TO-V5-DEST
(Invitrogen). Flag tagged SirT3 was generated by PCR
ampliﬁcation with ﬂanking EcoRI sites and a Flag tag in
the reverse primer. The PCR product was gel puriﬁed
(Qiagen, Valencia, CA, USA) and ligated into EcoRI digested
pMSCV PIG (Addgene plasmid 21645, Addgene, Cambridge,
MA, USA) or EcoRI digested pLVX-tight puro (Clontech,
Mountain View, CA, USA). The pMA2640 (Addgene plasmid
25434) was used to stably express rtTA. SirT3 pLKO.1 shRNA
vectors were purchased from Sigma (sequence 1 is
TRCN0000038892 and sequence 2 is TRCN0000038893) and
the control pLKO.1 scramble vector was obtained from
Addgene (plasmid 1864). We used pMD2.G (Addgene plasmid
12259) and psPAX2 (Addgene plasmid 12260) to generate
virus using the above described transfer vectors.
Gene reporter assay
HIF-mediated transcriptional activity was measured using
HRE-luc plasmid. HRE-luc is three copies of a HIF
response element (3 HRE) from the pgk-1 gene cloned into
the pGL2-Basic plasmid (Promega, Madison, WI, USA). Cells
(2 10
5) were plated into each well of a six-well plate and the
next day cells were transfected with 1mg HRE-luc and 0.05mg
of pRL-TK plasmid using Fugene HD (Roche, Indianapolis,
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OncogeneIN, USA) according to the manufacturer’s protocol. After
24h, cells were subjected to conditions for 16h before lysates
were collected. Luciferase values were determined using a dual-
luciferase reporter assay kit (Promega) according to the
manufacturer’s protocol. Values for ﬁreﬂy luciferase were
normalized to Renilla luciferase under the control of the
thymidine kinase promoter in the pRLTK vector.
ROS determination
Cells (10
5) were plated into each well of a 24-well plate and the
next day the cells were washed once with phosphate-buffered
saline and labeled at 371C for 30min in phenol red-free
Dulbecco’s Modiﬁed Eagle Medium (Sigma) containing 10mM
dihydroethidium (Invitrogen). After 30min, plates were placed
on ice and cells were trypsinized and resuspended in
dihydroethidium free labeling media. Fluorescence was mea-
sured using FACScan cytometer (BD Biosciences, Woburn,
MA, USA) and the geometric mean ﬂuorescence intensity of a
minimum of 10000 cells was analyzed in each sample. Mean
ﬂuorescence intensity values were corrected for autoﬂuores-
cence by normalizing to unlabeled cells.
SDS–polyacrylamide gel electrophoresis and western blots
Total cell lysates were prepared by washing cells with cold
phosphate-buffered saline and then the cells were lysed
with RIPA Buffer (50mM Tris-HCL pH8, 150mM NaCl,
1m M EDTA, 0.1% SDS, 0.1% NaDeOC, 1% NP40, complete
protease inhibitor (Roche)). At least 50mg of total cell lysates
was run on a SDS–polyacrylamide gel electrophoresis and
then proteins were transferred to polyvinylidene diﬂuoride
(Millipore, Billerica, MA, USA). Membranes were incubated
with appropriate primary antibodies overnight at 41C.
Antibodies used are as follows: human HIF-1a (BD Bios-
ciences), a-tubulin (Sigma), Flag (Sigma), V5 (Abcam, Cam-
bridge, MA, USA) and Flag (Sigma).
Quantitative real time PCR
RNA was isolated using Aurum Total RNA Mini Kit (Biorad,
Hercules, CA, USA) and complementary DNA was generated
from 1mg RNA using Retroscript Kit (Ambion, Austin, TX,
USA) according to manufacturer’s protocols. Complementary
DNA was analyzed using the Light Cycler 480 II (Roche) with
SYBR Green master mix from Biorad. Primers sequences were
obtained from Primer Bank (http://pga.mgh.harvard.edu/
primerbank/citation.html).
Xenografts
A volume of 200ml of phosphate-buffered saline containing
5 10
6 HCT116 cells were injected into either ﬂank of 7-week-
old Nu/Nu mice (Jackson Labs, Bar Harbor, ME, USA). The
control scr expressing cells were injected on the left or right
side of the mouse and the SirT3 knockdown cells were injected
on the other side of the same mouse. When tumors surpassed
2mm we measured them with calipers in two dimensions
(width W and length L) 2–3 times a week. The average tumor
volume was calculated as V¼L W
2 0.52. At the end of the
experiment mice were euthanized and tumors were harvested
and weighed. Animals treated with NAC had their drinking
water supplemented with 40mM NAC as previously described
(Gao et al., 2007). Doxycycline treatment was performed by
feeding animals 0.625g/kg doxycycline (Rodent Diet 2018, 625
Doxycycline, Harlan laboratories, South Easton, MA, USA).
All animal care followed approved institutional guidelines of
MIT. All animal experiments were approved by the Committee
on Animal Care at MIT.
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